Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05497284 · ClinicalTrials.gov registry record · Phase 2
To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT05497284 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 46 participants.
The verdict
NCT05497284, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis
Interventions
- DRUG Placebo
- DRUG Standard of Care (SoC)
- DRUG LTP001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2022-11-10 |
| Est. Completion | 2024-09-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05497284
The ClinicalTrials.gov registry entry for NCT05497284 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05497284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05497284 about?
NCT05497284 is a clinical study titled "To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF". A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis
What is the current status of trial NCT05497284?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2022-11-10. Estimated completion is 2024-09-26.
What interventions are being tested in trial NCT05497284?
The interventions under investigation include: Placebo (DRUG), Standard of Care (SoC) (DRUG), LTP001 (DRUG).
Who is sponsoring clinical trial NCT05497284?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.